



# **36th EAsDEC Annual Meeting**

28–30 May 2026 · Oslo, Norway

**P R O G R A M M E**

# THURSDAY 28 MAY 2026

**15:30**      **Registration**

**16:00**      'NORTHERN (high) - LIGHTS in diabetes and DR research. An Eye on the Past, Present and Future'  
Dr Kåre Birkeland, Prof. of internal medicine & Dr Goran Petrovski, Prof. of ophthalmology

**16:45**      Roche sponsored mini-symposium - Evolving Treatment Strategies in Diabetic Macular Edema: Clinical Experience with Faricimab

**17:30**      **Bus to Welcome Reception** — Oslo City Hall  
Buses will transport attendees from Ullevål Meet to Oslo City Hall

**18:30 –**      **36<sup>th</sup> EAsDEC Annual Meeting Opening Ceremony**  
**20:00**      Welcome reception at Oslo City Hall (Nobel Ceremony Hall)

# FRIDAY 29 MAY 2026

## 08:00 Registration

All posters must be mounted between 08:00 – 08:45, to ensure they are in place for the first session.

## 09:00 Welcome — Dag Fosmark

## 09:15 SESSION 1: CLINICAL

**Moderators:** Stela Vujosevic and Christina Rennie

**Rennie, UK.** Optimising Anti-VEGF and corticosteroid use in centre-involved diabetic macular oedema: A validated UK Delphi consensus supporting individualised patient care (5 mins + 2 mins Q&A)

**Rapid Fire** (4 min / presentation)

**Vujosevic, Italy.** A randomized, active-controlled clinical trial of fluocinolone acetonide 0.19-mg intravitreal implant for diabetic macular oedema: visual acuity outcomes based on lens status -- Results from the NEW DAY study

**Charles O'Donovan, UK.** Switching from Aflibercept to Faricimab in diabetic macular oedema: Real-world outcomes

**Huber, Austria.** One-year real-world outcomes after switching from Aflibercept to Faricimab in diabetic macular oedema

**Ahmed, UK.** Intravitreal Faricimab for treatment of diabetic macular oedema: Impressive real-world outcomes sustained at 52 weeks

**Salvatore, UK.** Real-world dexamethasone implant (DEX-I) injection burden in diabetic macular oedema: insights from 10 UK sites using the mediSIGHT EMR

**Peto, UK.** Two-year effectiveness, durability and safety of Faricimab in eyes with diabetic macular oedema: Results from the UK FARWIDE-DME Study

**Questions & discussion** (12 min)

**Moderators' conclusions** (2 min)

## 10:00 Coffee Break

## 10:45 DEBATE

'A paradigm shift is needed in trial design for intravitreal agents in DME'

**For:** Reinier Schlingemann **Against:** Philip Burgess

## 11:15 SESSION 2: Imaging and Artificial Intelligence

**Moderators:** Goran Petrovski and Maria Cicinelli

**Short talk** (10 mins)

**Goran Petrovski.** 'Implementation of Artificial Intelligence in DR screening in Norway'

**Free papers** (5 min + 2 min Q&A / presentation)

**McNally, UK.** Creation of a validated OCT fluid segmentation gold standard to support AI development in DMO

**Cicinelli, Italy.** Intraretinal fluid redistribution as a dynamic biomarker of treatment response in diabetic macular oedema

**Jeppesen, Denmark.** Visual acuity is reduced with increasing central retinal thickness, higher age and female sex in diabetic macular oedema

**Widmann-Sedlitzky, Austria.** Hard exudate and hyperreflective foci dynamics across anatomical response patterns in faricimab-treated diabetic macular oedema

**Pignataro, Italy.** Microaneurysm reflectivity as a prognostic biomarker for intravitreal treatment response in diabetic retinopathy

**Almeida, Portugal.** Retinal microvascular and neuronal findings in type 2 diabetes: Results from a screening programme

**Marques, Portugal.** Two-year longitudinal progression of microvascular changes in moderate to severe non-proliferative diabetic retinopathy: The RICHARD Study

**Anne Katrin Sjølie Student Prize**

**Dag Fosmark.** Anne Katrin Sjølie Memorial talk

**Kunze, Austria.** Diabetic vascular and inflammatory microstructures followed over time by high-resolution adaptive optics imaging (5 min)

**Moderators' conclusions** (5 min)

## 12:30 Lunch Buffet

### Poster Section 1. Clinical A

**Moderators:** Maria Grazia Pignataro and Anne Kari Kvernebo

**Gruszka-Goh, UK.** Injection treatment intervals in eyes with DMO switching to 8mg Aflibercept

**Wales, UK.** Can telephone consultations enhance the diabetic ophthalmology service?

**Bettencourt, Portugal.** Early-onset high-risk proliferative diabetic retinopathy in type 1 diabetes: a rare case and 20-year cohort analysis

**Chatziralli, Greece.** Randomized, controlled study to investigate the efficacy and safety of resveratrol vitamin supplements in patients with non-proliferative diabetic retinopathy without diabetic macular oedema (REVOLUTION study)

**Tarasi, Romania.** Early worsening of diabetic retinopathy after rapid glycaemic control: A case report highlighting vitamin D as a nutritional intervention

**Masalkhi, Republic of Ireland.** Diabetic Retinopathy Screening Outcomes in Pregnancy: A Review of the Pregnancy Pathway in the Irish National Diabetic Retinal Screening Programme.

### Poster Section 2. Clinical B

**Moderators:** Andreas Pollreis and Morten C. Moe

**Ferreira, Portugal.** Fluocinolone acetonide after glaucoma surgery in diabetic macular oedema: clinical risk or safe therapeutic option?

**Saraan, UK.** Effectiveness and safety of intravitreal steroid therapy for diabetic macular oedema: A clinical audit at the Royal Liverpool University Hospital.

**Peto, UK.** Injection frequency, loading dose completion, and 12-month outcomes of anti-VEGF treatment in diabetic macular oedema

**Madeira, Portugal.** Sustained disease control with fluocinolone acetonide implant in refractory diabetic macular oedema: Real-world evidence

**Earley, UK.** Diabetic and surgical factors associated with progression of pseudophakic diabetic retinopathy, a 5 year follow up study

**Bettencourt, Portugal.** Acute bilateral cystoid macular oedema following SARS-CoV-2 vaccination in a type 1 diabetic patient: A case report

**Tomić, Croatia.** Citicoline shows potential in reducing the hard exudates in diabetic retinopathy

**Similie, Denmark.** Rapid glycaemic reduction and early worsening of diabetic retinopathy in type 1 diabetes: A Danish nationwide cohort study

### Poster Section 3. Imaging and Artificial Intelligence

**Moderators:** Inês Pereira Marques and Signe Jeppesen

**Carotenuto, Italy.** OCT and OCTA phenotypes as predictors of durable response to aflibercept 8 mg in diabetic macular oedema: An 18-month real-world analysis

**Chiosi, Italy.** Artificial intelligence--guided inflammatory biomarkers to support a proactive dexamethasone implant regimen in diabetic macular oedema: A real-world study analysis

**Pinto, Portugal.** Microaneurysm counting as a biomarker for the hyperperfusion stage of non-proliferative diabetic retinopathy

### Poster Section 4. Screening

**Moderators:** Geir Bertelsen and Philip Burgess

**Davies, UK.** Feasibility of an alternative pathway for hospital referrals from Diabetic Eye Screening Wales (DESW) for people suspected with sight-threatening diabetic eye disease (diabetic maculopathy)

**Babić, Croatia.** Design and implementation of a national programme for diabetic retinopathy screening in Croatia: A telemedicine-based population health initiative

**Sharif, Sweden.** Quantifying diabetic retinopathy in the elderly: Long term screening outcomes

**Jamison, UK.** Rates of retinopathy and maculopathy at diabetes clinics in three regions of Tanzania

**Meredith, UK.** A review of people within the English National Diabetic Eye Screening Programme who were screened without mydriasis

**Saesund, Norway.** Implementation of diabetic retinopathy screening in the Oslo Region, Norway: A Three-year pilot study

**Rahim, UK.** Post-COVID-19 barriers to diabetic retinopathy screening attendance: An updated systematic review

**Piatti, Italy.** Implementation of a reading centre for diabetic retinopathy screening in Piedmont region, Italy

**Sproule, UK.** The Diabetes Complications in Senior Adults (DCSA) Study: Diabetic eye disease in people over the age of 80 with diabetes in Northern Ireland

**Ao, China.** Establishing a regional diabetic eye screening system in Hinggan League, China

### 14:30 Coffee Break

## 15:00 SESSION 3: Laboratory Experimental A

**Moderators:** Patrice Fort and Imre Lengyel

(5 min + 2 min Q&A / presentation)

**Fort, USA.** The Mary Tyler Moore Vision Initiative Biorepository and Resource Center: Deep structural analysis of the neurovascular unit components as a function of diabetic retinal disease

**Lengyel, UK.** A Type 1 Diabetic Abcc6  $\pm$  mouse model reveals mechanisms of ectopic calcification and therapeutic potential of oral pyrophosphate

**Su, Germany.** VE-cadherin Y685 phosphorylation is critical for neurovascular unit regulation during retinal angiogenesis

**Ambrosio, Portugal.** Negative impact of a primary immune challenge triggered by lipopolysaccharide on the retina of diabetic rats

**Lin, Germany.** MDM2 regulates integrin  $\beta$ 8 expression in mouse diabetic retina

**Arroba, Spain.** Proteomic and inflammatory signatures associated with diabetic retinopathy in type 1 diabetes mellitus

**Moderators' conclusions** (3 min)

**15:45** **KEYNOTE: Professor emeritus. Trond G Jenssen, Nephrologist, Rikshospitalet, Oslo University Hospital**

'An Eye for the Kidney' (20 mins + 10 mins Q&A)

**16:15** **Eva Kohner Lecture: Professor, dr. med. Toke Bek, Eye dept., Aarhus University Hospital, Denmark. Introduced by RS**

"To look - may be to overlook - when we try to understand diabetic retinopathy" (20 mins + 10 mins Q&A)

**16:45** **AGM + Lithuania introduction**

**Vilma Jurate Balciuniene.** Lithuania introduction

**17:15** **Close**

**17:30 –** **Conference Dinner at Sporten** - nestled in the hills of Oslo

**22:00** Buses will transport attendees from the conference venue (Ullevål Meet) to Sporten and back.

# SATURDAY 30 MAY 2026

## 09:00 SESSION 4: Screening

**Moderators:** Maja Gran Erke, Geir Bertelsen and Laura Cushley

**Short Talk** (7 min / presentation)

**Maja Gran Erke, Norway.** Update on diabetic eye screening in Norway

**Jordan, UK.** NHS Diabetic Eye Screening (DES) Research and Innovation Needs Assessment (RINA)

**Discussion** (5min)

**Free Papers** (5 min / presentation)

**Borjan, Croatia.** Proliferative Diabetic Retinopathy in Young-Onset Type 1 Diabetes in Croatia: Risk Factors and a Predictive Economic Model for National Screening

**Haidar, UK.** Progression of diabetic retinopathy from referral to treatment or vision loss: External validation, update and net clinical benefit of a multivariable prediction model

**Cushley, UK.** Diabetes Complications in Senior Adults (DCSA) Study: investigating diabetic eye disease, knowledge and opinions in people over 80 in Northern Ireland

**Vrabec, Croatia.** First twelve-month results of diabetic retinopathy screening in Croatia: what we have done and achieved

**Discussion & moderators' conclusions** (6 min)

## 09:45 SESSION 5: Translational

**Moderators:** Ingeborg Klaassen and Eleni Beli

(6 min + 2 min Q&A / presentation)

**Jansson, Norway.** Light-adapted full-field electroretinography predicts diabetic retinopathy progression: A 10-year prospective cohort study

**Peterson, Denmark.** The amplitude of spontaneous diameter oscillations in retinal arterioles is increased in patients with vision threatening diabetic retinopathy

**Beli, UK.** The role of microglia circadian clock in diabetic retinopathy

**Klaassen, The Netherlands.** Retinal and cerebral microvascular changes in diabetes and Alzheimer's disease

**Besic, Denmark.** Clinical interpretation of inner retinal phenotypes in children and young adults with type 1 diabetes

**Discussion & moderators' conclusions** (5 min)

## 10:30 Coffee Break

**11:00 KEYNOTE: Per M Thorsby, Professor in medical biochemistry, Medical chair of department Hormone Laboratory, Specialised in endocrinology and internal medicine, Oslo University Hospital**

'Early detection of diabetes - finding the patient before the disease'

**11:25 KEYNOTE: Lars Krogvold, MD, PhD, Head of Diabetes Unit, Paediatric Dept., Oslo University Hospital**

Prevention and screening of type 1 diabetes

## 11:50 SESSION 6: Research Horizons

**Moderators:** Dag Fosmark and Mojca Urbančič

(6 min + 2 min Q&A / presentation)

**Torm, Denmark.** Retinal neurophysiological and microvascular parameters in young patients with type 1 diabetes

**Hellgren, Sweden.** Methods to detect change in visual fields in diabetic patients followed over a ten-years period

**Toma, Italy.** Evaluation of quality of life with a novel computerised system and visual function in patients with centre-involving diabetic macular oedema

**Al-Zubaidy, UK.** Predicting anti-VEGF outcomes in centre-involving diabetic macular oedema using regression and multimodal deep learning: A real-world NHS cohort

**Urbančič, Slovenia.** Association between macular pigment optical density, diabetes, and diabetic retinopathy

**Yu, China.** A gold nano-array SERS platform integrated with aptamer-antibody recognition enables non-invasive diagnosis and specific screening of diabetic retinopathy via tear biomarkers

**Discussion & moderators' conclusions** (7 min)

**12:45 Poster Prize & Closing Remarks — Reinier Schlingemann**

**13:00 Farewell**

Join us for a standing lunch before you begin your journey home.